Salt Lake City, UT, United States of America

Venkataswamy Sorna

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignee: University of Utah Research Foundation. Active years: 2013-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Venkataswamy Sorna. Retrieved from https://idiyas.com/inventor/venkataswamy-sorna

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 30.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 15(Granted Patents)

Company Filing History:

10 out of 1,687

University of Utah Research Foundation

patents

Years Active: 2013-2017

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9828376 - Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors (2017-11-28),

2. 9642857 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2017-05-09),

3. 9556170 - [object Object] (2017-01-31),

4. 9555024 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2017-01-31),

5. 9296703 - Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors (2016-03-29),

6. 9266838 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2016-02-23),

7. 9206176 - Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors (2015-12-08),

8. 8987335 - Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors (2015-03-24),

9. 8703767 - Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors (2014-04-22),

10. 8569511 - Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase (2013-10-29),

Title: Venkataswamy Sorna: Innovator in Pharmaceutical Chemistry

Introduction

Venkataswamy Sorna is a prominent inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific kinases and enzymes involved in various diseases. With a total of 10 patents to his name, Sorna's work is paving the way for innovative treatments.

Latest Patents

One of Sorna's latest patents is for "Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors." This invention relates to compounds that serve as inhibitors of the BTK kinase, which is crucial for treating disorders associated with its dysfunction. The patent outlines synthetic methods for creating these compounds, as well as pharmaceutical compositions that include them. Another notable patent is for "Substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors." This invention focuses on methods for treating disorders of uncontrolled cellular proliferation, including cancer, by administering these specific analogs to affected individuals.

Career Highlights

Venkataswamy Sorna is affiliated with the University of Utah Research Foundation, where he conducts his research and development work. His innovative approach to pharmaceutical chemistry has garnered attention in the scientific community, and his patents reflect his commitment to advancing medical treatments.

Collaborations

Sorna collaborates with notable colleagues, including Hariprasad Vankayalapati and Sunil Sharma. Their combined expertise enhances the research efforts at the University of Utah Research Foundation, contributing to the development of groundbreaking therapies.

Conclusion

Venkataswamy Sorna's contributions to pharmaceutical chemistry through his patents and research are significant. His work not only showcases his innovative spirit but also holds promise for future medical advancements.

Profile summary based on public USPTO records.